HFREF - HEART FAILURE WITH REDUCED EJECTION FRACTION
Clinical trials for HFREF - HEART FAILURE WITH REDUCED EJECTION FRACTION explained in plain language.
Never miss a new study
Get alerted when new HFREF - HEART FAILURE WITH REDUCED EJECTION FRACTION trials appear
Sign up with your email to follow new studies for HFREF - HEART FAILURE WITH REDUCED EJECTION FRACTION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Nerve-Stimulating implant offers hope for failing hearts
Disease control Not yet recruitingThis study is testing a small implanted device called Barostim in adults with severe heart failure who still have symptoms despite taking all recommended medications. The device stimulates nerves in the neck to help balance the body's automatic systems and improve how the heart w…
Matched conditions: HFREF - HEART FAILURE WITH REDUCED EJECTION FRACTION
Phase: NA • Sponsor: Columbia University • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
Apple watch trial aims to keep heart patients out of hospital
Disease control Not yet recruitingThis study is testing whether using data from wearable devices like the Apple Watch can help doctors remotely manage medications for people with both heart failure and atrial fibrillation. The goal is to see if this approach leads to better medication adjustments and fewer hospit…
Matched conditions: HFREF - HEART FAILURE WITH REDUCED EJECTION FRACTION
Phase: NA • Sponsor: Beijing Anzhen Hospital • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New IV therapy aims to keep severe heart failure patients stable
Disease control Not yet recruitingThis study is testing whether a continuous intravenous (IV) infusion of a medicine called alprostadil can help keep people with severe, advanced heart failure stable and out of the hospital. About 400 participants will receive either the active medicine or a placebo (inactive sol…
Matched conditions: HFREF - HEART FAILURE WITH REDUCED EJECTION FRACTION
Phase: PHASE3 • Sponsor: Biopeutics Co., Ltd • Aim: Disease control
Last updated Mar 06, 2026 15:38 UTC